Related Experiment Video
Updated: May 5, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
1.1K
Salvage brachytherapy for recurrent prostate cancer
Carlos Vargas1, Douglas Swartz2, Apoorva Vashi2
1Florida Center for Prostate Care, Jacksonville, FL.
Brachytherapy
|December 4, 2013
Summary
Salvage brachytherapy offers excellent local control for recurrent prostate cancer after initial radiation. Early treatment and non-castration-resistant disease significantly improve outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Evaluating salvage prostate brachytherapy for locally recurrent prostate cancer post-external beam radiation.
- Analyzing 69 patients with pathologically proven recurrence >2 years after initial therapy and no distant disease.
Discussion:
- Salvage brachytherapy demonstrates significant potential for managing local recurrences.
- Early treatment and non-castration-resistant prostate cancer (CRPC) are key predictors of success.
- Low rates of severe toxicity observed, highlighting safety profile.
Key Insights:
- 5-year biochemical control rates: 85.6% (low-risk), 74.8% (intermediate-risk), 66% (high-risk).
- 5-year biochemical control: 73.8% (non-CRPC) vs. 22% (CRPC).
- Early treatment significantly better than delayed treatment (p<0.05).
Outlook:
- Salvage brachytherapy is a viable option for select patients with local recurrence.
- Further research into optimizing treatment timing and patient selection for CRPC is warranted.
- Continued monitoring of long-term outcomes and toxicity is essential.
